I wanted to take this opportunity to provide you with an update on some of the activities and achievements in the Arthritis Center this year across each of our three mission areas: patient care, research, and education.
Apremilast (Otezla®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). It is the first oral medication in the U.S. with an approved indication for the treatment of PsA. The recommended dose is 30 mg BID
Clifton Bingham, MD and Vicky Ruffing, RN discuss the Seasonal and Novel N1N1 flu and potential impact on the rheumatology community. Information is focused on the immunizations, delivery systems, and targeted populations.